The cost-effectiveness of cardiac monitoring in breast cancer patients who have received cardiotoxic therapies
It has been known that anthracycline-based chemotherapy has the potential to cause cardiac dysfunction in breast cancer patients; however, recently evidence has shown that the addition of trastuzumab increases this risk. The study objective was to compare the cost-effectiveness of monitoring for car...
| Main Author: | |
|---|---|
| Format: | Others |
| Language: | English |
| Published: |
2012
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/2152/ETD-UT-2012-05-5626 |